OrbiMed

InspireMD is a medical device company headquartered in Tel Aviv, Israel, specializing in the development and commercialization of its proprietary MicroNet stent platform technology for treating vascular and coronary diseases. The company offers products such as the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection system, intended for patients with acute coronary syndromes. InspireMD is also working on the NGuard neurovascular flow diverter, which aims to divert blood flow away from cerebral aneurysms. The company generates most of its revenue from the sales of the CGuard system, which integrates MicroNet technology with a self-expandable nitinol stent. Its products are distributed through local partners in various regions, including Europe, Latin America, the Middle East, and Asia.

Magenta Medical Ltd., founded in 2012 and based in Kadima, Israel, specializes in developing innovative device solutions for the treatment of acute and chronic heart failure. The company's primary focus is on a temporary venous catheter-based therapy designed specifically for patients experiencing acute decompensated heart failure. By addressing critical needs within this medical field, Magenta Medical aims to improve patient outcomes through its advanced therapeutic technologies.

DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). By addressing the underlying causes of MGD, Azura aims to improve the health and quality of life for millions affected by this and other ocular surface diseases, where effective treatment options are often limited. The company is advancing a unique portfolio of compounds in conjunction with a novel drug delivery platform, enabling healthcare professionals to better manage these conditions. Based in Tel Aviv-Yafo, Israel, Azura also has operational presence in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of novel ocular therapies.

NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.

MobileODT Ltd specializes in developing optical diagnostic devices and software focused on early cancer detection, particularly cervical cancer. The company's flagship product, the EVA COLPO, is a portable, internet-connected colposcope that is FDA-cleared and designed for ease of use. MobileODT also offers EVA SANE, a secure platform for managing patient information, and EVA WELL, a digital visualization tool for gynecologic exams. Their offerings include a mobile application for remote image capture and patient tracking, along with a cloud-based portal for collaboration and reporting. In addition, the company provides tools for documenting violence and abuse and plans to expand its product line to cover other medical areas such as ENT and dermatology. Established in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has gained recognition in various markets, particularly the United States, where it is becoming a standard for visual diagnostics in healthcare settings.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.

TytoCare Ltd. is a healthcare technology company that develops handheld devices and applications for on-demand medical examinations and remote diagnoses. Founded in 2012 and based in Netanya, Israel, with an office in New York, the company offers three main telehealth products: TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote care settings. These tools enable users to conduct self-examinations of various health conditions, such as ear infections, respiratory issues, and abdominal pain, by assessing the heart, lungs, skin, throat, ears, and body temperature. The platform facilitates virtual consultations by connecting patients with healthcare professionals, allowing for diagnosis and prescriptions as needed. TytoCare's technology incorporates a cloud-based data repository, analytics, and machine learning algorithms to enhance user experience and diagnostic accuracy. The company has established a strategic partnership with Novant Health to further its mission of making healthcare accessible and convenient.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR to address neurodegenerative and neuroinflammatory diseases. The company has successfully developed a series of novel molecules through innovative computational methods, followed by validation in clinically relevant assays. These inhibitors aim to improve memory consolidation and enhance long-term memory in patients suffering from these conditions. ProteKt Therapeutics has raised $4 million in a pre-A funding round and is a graduate of the FutuRx accelerator, which supports emerging biotechnology ventures.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

TytoCare Ltd. is a healthcare technology company that develops handheld devices and applications for on-demand medical examinations and remote diagnoses. Founded in 2012 and based in Netanya, Israel, with an office in New York, the company offers three main telehealth products: TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote care settings. These tools enable users to conduct self-examinations of various health conditions, such as ear infections, respiratory issues, and abdominal pain, by assessing the heart, lungs, skin, throat, ears, and body temperature. The platform facilitates virtual consultations by connecting patients with healthcare professionals, allowing for diagnosis and prescriptions as needed. TytoCare's technology incorporates a cloud-based data repository, analytics, and machine learning algorithms to enhance user experience and diagnostic accuracy. The company has established a strategic partnership with Novant Health to further its mission of making healthcare accessible and convenient.

Atox Bio Inc. is a biotechnology company established in 2003, based in Ness Ziona, Israel, with an additional office in North Carolina. The company specializes in developing immunomodulators aimed at treating critically ill patients suffering from acute and life-threatening conditions due to severe infections and inflammation. Atox Bio focuses on novel modulators of the immune response that target interconnected pathways of both the adaptive and innate immune systems, which are crucial in addressing infectious diseases, inflammatory diseases, and ischemia/reperfusion injuries.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

RDD Pharma, Ltd. is a pharmaceutical company that focuses on developing and commercializing therapeutics for anorectal diseases and gastrointestinal disorders. Established in 2008 and based in Tel-Aviv, Israel, with an office in New York, the company specializes in creating targeted pharmacological treatments for conditions such as chronic anal fissures, fecal incontinence, and pruritus ani. RDD Pharma employs specialized formulation and delivery techniques to address the unique anatomical and physiological challenges associated with these conditions. By developing effective drugs, the company aims to provide healthcare professionals with options that enable patients to achieve painless and rapid relief from their ailments. As of April 2020, RDD Pharma operates as a subsidiary of Innovate Biopharmaceuticals, Inc.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). By addressing the underlying causes of MGD, Azura aims to improve the health and quality of life for millions affected by this and other ocular surface diseases, where effective treatment options are often limited. The company is advancing a unique portfolio of compounds in conjunction with a novel drug delivery platform, enabling healthcare professionals to better manage these conditions. Based in Tel Aviv-Yafo, Israel, Azura also has operational presence in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of novel ocular therapies.

MobileODT Ltd specializes in developing optical diagnostic devices and software focused on early cancer detection, particularly cervical cancer. The company's flagship product, the EVA COLPO, is a portable, internet-connected colposcope that is FDA-cleared and designed for ease of use. MobileODT also offers EVA SANE, a secure platform for managing patient information, and EVA WELL, a digital visualization tool for gynecologic exams. Their offerings include a mobile application for remote image capture and patient tracking, along with a cloud-based portal for collaboration and reporting. In addition, the company provides tools for documenting violence and abuse and plans to expand its product line to cover other medical areas such as ENT and dermatology. Established in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has gained recognition in various markets, particularly the United States, where it is becoming a standard for visual diagnostics in healthcare settings.

Mitoconix Bio Ltd develops a novel strategy to improve mitochondrial health as a disease modifying therapeutic for neurodegenerative diseases. The company was founded in 2016 and is based in Jerusalem, Israel.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.

SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.

Ornim, Inc. is a medical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, the company specializes in non-invasive patient monitoring devices focused on measuring blood flow and oxygen saturation in tissues. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology, which combines light and ultrasound to provide real-time, continuous measurements of cerebral blood flow and regional oxygen saturation. CerOx is notable for being the only device on the market that can simultaneously measure both parameters, while c-FLOW focuses solely on cerebral blood flow. These advanced monitoring solutions are designed to assist healthcare professionals in making informed decisions for neurological treatments and cardiac surgeries, ultimately improving patient care and reducing costs. Ornim holds multiple patents for its innovative technologies, which address the limitations of existing monitoring methods.

SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

TytoCare Ltd. is a healthcare technology company that develops handheld devices and applications for on-demand medical examinations and remote diagnoses. Founded in 2012 and based in Netanya, Israel, with an office in New York, the company offers three main telehealth products: TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote care settings. These tools enable users to conduct self-examinations of various health conditions, such as ear infections, respiratory issues, and abdominal pain, by assessing the heart, lungs, skin, throat, ears, and body temperature. The platform facilitates virtual consultations by connecting patients with healthcare professionals, allowing for diagnosis and prescriptions as needed. TytoCare's technology incorporates a cloud-based data repository, analytics, and machine learning algorithms to enhance user experience and diagnostic accuracy. The company has established a strategic partnership with Novant Health to further its mission of making healthcare accessible and convenient.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.

Atox Bio Inc. is a biotechnology company established in 2003, based in Ness Ziona, Israel, with an additional office in North Carolina. The company specializes in developing immunomodulators aimed at treating critically ill patients suffering from acute and life-threatening conditions due to severe infections and inflammation. Atox Bio focuses on novel modulators of the immune response that target interconnected pathways of both the adaptive and innate immune systems, which are crucial in addressing infectious diseases, inflammatory diseases, and ischemia/reperfusion injuries.

Medigus Ltd. is a medical device company based in Omer, Israel, that specializes in developing and marketing innovative minimally invasive endo-surgical tools and direct visualization technology. Founded in 1999, the company primarily focuses on the treatment of gastroesophageal reflux disease (GERD), a common chronic condition. Medigus has created an endoscopic system known as the SRS, which integrates a miniaturized video camera, surgical stapler, and ultrasonic alignment sights into a single device. This system allows gastroenterologists and surgeons to perform a partial anterior fundoplication endoluminally, significantly transforming GERD treatment by reducing reliance on traditional open or laparoscopic surgeries. In addition to its proprietary products, Medigus designs and manufactures endoscopy systems for partner companies, offering a range of technologies including small video cameras, video processors, and various types of endoscopes for diverse endoscopic procedures. The company operates globally across the United States, Europe, Asia, and other international markets.

Keystone Heart is a developer and manufacturer of medical devices aimed at enhancing patient care in cardiovascular procedures. The company specializes in creating embolic cerebral protection devices designed to safeguard the brain from emboli, thereby minimizing the risk of brain infarcts, stroke, neurocognitive decline, and dementia during procedures such as transcatheter aortic valve replacement and atrial fibrillation ablation. By focusing on the preservation of cerebral function, Keystone Heart aims to improve procedural outcomes and quality of life for patients undergoing structural heart interventions. The company's commitment to innovative technology and clinical research positions it as a potential leader in the field of cerebral protection during cardiac surgeries.

TytoCare Ltd. is a healthcare technology company that develops handheld devices and applications for on-demand medical examinations and remote diagnoses. Founded in 2012 and based in Netanya, Israel, with an office in New York, the company offers three main telehealth products: TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote care settings. These tools enable users to conduct self-examinations of various health conditions, such as ear infections, respiratory issues, and abdominal pain, by assessing the heart, lungs, skin, throat, ears, and body temperature. The platform facilitates virtual consultations by connecting patients with healthcare professionals, allowing for diagnosis and prescriptions as needed. TytoCare's technology incorporates a cloud-based data repository, analytics, and machine learning algorithms to enhance user experience and diagnostic accuracy. The company has established a strategic partnership with Novant Health to further its mission of making healthcare accessible and convenient.

Ornim, Inc. is a medical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, the company specializes in non-invasive patient monitoring devices focused on measuring blood flow and oxygen saturation in tissues. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology, which combines light and ultrasound to provide real-time, continuous measurements of cerebral blood flow and regional oxygen saturation. CerOx is notable for being the only device on the market that can simultaneously measure both parameters, while c-FLOW focuses solely on cerebral blood flow. These advanced monitoring solutions are designed to assist healthcare professionals in making informed decisions for neurological treatments and cardiac surgeries, ultimately improving patient care and reducing costs. Ornim holds multiple patents for its innovative technologies, which address the limitations of existing monitoring methods.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv, Israel, established in 2009. The company focuses on developing and commercializing innovative treatments primarily for gastrointestinal and infectious diseases. RedHill markets several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for Helicobacter pylori infection, and Aemcolo for travelers’ diarrhea. In addition to its marketed products, the company is advancing multiple late-stage investigational programs. These include RHB-204, which targets pulmonary nontuberculous mycobacterial infections; opaganib, a selective inhibitor with ongoing studies for COVID-19, prostate cancer, and cholangiocarcinoma; and RHB-104 for Crohn's disease. Other projects involve RHB-102 for acute gastroenteritis and gastritis, RHB-107 for cancer and inflammatory gastrointestinal diseases, and RHB-106, an encapsulated bowel preparation. RedHill Biopharma emphasizes acquiring, developing, and improving existing drugs and orphan drugs through its innovative approach to drug formulation and regulatory pathways.

Treato Ltd. operates Treato, provides social health patient intelligence solutions. The company offers health information platform that aggregates patient experiences from the Internet; and organizes them into usable insights for patients, healthcare professionals, pharma companies, and other healthcare organizations. Its Treato platform collects data from healthcare social media sites and forums; analyzes the information; and provides a window into patients’ thoughts and attitudes. The company also provides Treato Pharma, a brand intelligence service for pharma marketers and agencies to provide analytics and insights into patients’ thoughts and attitudes. Its Treato Pharma also interprets the patient voice, understands patient behaviors, gains competitive insights, extracts the right messages, expends effort into the right places, and engages in real time. Treato Ltd. was founded in 2008 and is based in Yehud, Israel.

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company’s development pipeline includes several therapeutic candidates, such as BL-8040, a peptide aimed at treating solid tumors and hematological malignancies, as well as facilitating stem cell mobilization. Another candidate, AGI-134, is an immuno-oncology agent designed for solid tumors, while BL-5010 is a proprietary applicator intended for the non-surgical removal of skin lesions. BioLineRx has established collaborations with notable organizations, including a partnership with MSD in the cancer immunotherapy field, and agreements with MD Anderson Cancer Center and Genentech Inc. to explore combinations of BL-8040 with existing therapies in clinical studies for pancreatic and other solid tumors. Founded in 2003, BioLineRx is dedicated to addressing unmet medical needs and improving treatment options in oncology.

cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.

Ornim, Inc. is a medical technology company based in Santa Clarita, California, with a research and development subsidiary in Israel. Founded in 2004, the company specializes in non-invasive patient monitoring devices focused on measuring blood flow and oxygen saturation in tissues. Its primary products, CerOx and c-FLOW, utilize patented UTLight technology, which combines light and ultrasound to provide real-time, continuous measurements of cerebral blood flow and regional oxygen saturation. CerOx is notable for being the only device on the market that can simultaneously measure both parameters, while c-FLOW focuses solely on cerebral blood flow. These advanced monitoring solutions are designed to assist healthcare professionals in making informed decisions for neurological treatments and cardiac surgeries, ultimately improving patient care and reducing costs. Ornim holds multiple patents for its innovative technologies, which address the limitations of existing monitoring methods.

SMT is a Herzliya Pituach, Israel-based medical device company founded in 2004. SMT is focused on the development and commercialization of procedural tools and accessories for use during TAVI and other complex percutaneous structural heart procedures.